Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes

MLA

P. H. Tossavainen, et al. Short-Term Administration of Pegvisomant Improves Hepatic Insulin Sensitivity and Reduces Soleus Muscle Intramyocellular Lipid Content in Young Adults with Type 1 Diabetes. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....02f51514f509541da14c10462b77d672&authtype=sso&custid=ns315887. Accessed 30 Dec. 2024.

APA

P. H. Tossavainen, Ajay Thankamony, David B. Dunger, D. Elleri, A. M. Umpleby, Alison Sleigh, Rachel M. Williams, Nicola Jackson, Carlo L. Acerini, & R. N. Dalton. (n.d.). Short-term administration of pegvisomant improves hepatic insulin sensitivity and reduces soleus muscle intramyocellular lipid content in young adults with type 1 diabetes.

Chicago

P. H. Tossavainen, Ajay Thankamony, David B. Dunger, D. Elleri, A. M. Umpleby, Alison Sleigh, Rachel M. Williams, Nicola Jackson, Carlo L. Acerini, and R. N. Dalton. 2024. “Short-Term Administration of Pegvisomant Improves Hepatic Insulin Sensitivity and Reduces Soleus Muscle Intramyocellular Lipid Content in Young Adults with Type 1 Diabetes.” Accessed December 30. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....02f51514f509541da14c10462b77d672&authtype=sso&custid=ns315887.